GlassScriptPhysician profile
Melanie Clark
NPI 1245593854
$23,292.85
in general payments reported to CMS, 2019-2025
21 companies · $8,521 in 2025
The $8,521 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $4,038 · 2021: $1,751 · 2022: $2,600 · 2023: $1,665 · 2024: $4,005 · 2025: $8,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,440 · Long Term Medical Supply Or Device Loan: $881 · Travel and Lodging: $290 · Food and Beverage: $185 · Education: $5.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,390.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,440.00 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Travel and Lodging | $289.90 |
| Food and Beverage | $185.00 |
| Education | $5.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $8,520.86 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $7,987.35 | 2019-2024 | Truqap, Enhertu |
| Pfizer INC. | $2,983.81 | 2019-2024 | |
| Daiichi Sankyo INC. | $1,100.00 | 2022 | |
| Puma Biotechnology, INC. | $1,032.39 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $971.59 | 2019-2024 | |
| Genentech USA, INC. | $177.99 | 2019 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Merck Sharp & Dohme LLC | $83.65 | 2019-2020 | |
| Fortovia Therapeutics, INC. | $48.23 | 2019 | |
| Tersera Therapeutics LLC | $32.62 | 2019 | |
| Eisai INC. | $30.40 | 2019 | |
| Clovis Oncology, INC. | $25.65 | 2019-2020 | |
| Janssen Biotech, INC. | $20.02 | 2019 | |
| Chiesi USA, INC. | $19.37 | 2024 | Kengreal, Cleviprex |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $15.93 | 2019 | |
| Foundation Medicine, INC. | $14.86 | 2019 | |
| Celgene Corporation | $14.69 | 2019 | |
| Lilly USA, LLC | $13.33 | 2019 | |
| Amgen INC. | $13.19 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.